Placebo to V940

DRUG3 trials

Sponsors

Merck Sharp & Dohme LLC

Conditions

MelanomaMuscle-invasive Urothelial CarcinomaNon-small cell lung cancer stage IV

Phase 2

A Phase 1/2 Study of V940 Plus Pembrolizumab With or Without Enfortumab Vedotin in Muscle-Invasive Urothelial Carcinoma (MIUC) (INTerpath-005)

Active, not recruitingCTIS2023-505658-17-00

Merck Sharp & Dohme LLCMuscle-invasive Urothelial Carcinoma

Start: 2024-04-16Target: 90Updated: 2025-10-06

A Phase 2, Randomized, Double-Blind, Placebo- and Active-Comparator-Controlled Clinical Study of V940 (mRNA-4157) Plus Pembrolizumab Versus Placebo Plus Pembrolizumab in Participants in First-Line Metastatic Melanoma (INTerpath-012)

RecruitingCTIS2024-519605-36-00

Merck Sharp & Dohme LLCMelanoma

Start: 2025-08-08Target: 97Updated: 2025-09-10

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of V940 in Combination With Pembrolizumab and Chemotherapy as First-Line Treatment for Participants With Metastatic Squamous NSCLC (INTerpath-013)

Not yet recruitingCTIS2025-520902-37-00

Merck Sharp & Dohme LLCNon-small cell lung cancer stage IV

Target: 15Updated: 2026-03-23